Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials

Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies

(2022) David L. Paterson et al.   Infectious Diseases and Therapy

OXA-48-Like β-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline

(2022) Sara E. Boyd et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia

(2020) Mercedes Delgado-Valverde et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

(2020) Matteo Bassetti et al.   LANCET INFECTIOUS DISEASES

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

(2020) Richard G Wunderink et al.   LANCET INFECTIOUS DISEASES

Stability of cefiderocol against clinically significant broad-spectrum oxacillinases

(2018) Laurent Poirel et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens

(2017) J. Dobias et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES